News

SirVir Ltd., an Aposense subsidiary in the field of respiratory viral infections announce the fulfillment of a $14M milestone investment from Access Industries. Prior to this transaction SirVir reached its scientific milestone when generating safety and efficacy data against the SARS CoV2 on a non-human primates model

The English translation of an interview on Ynet with Prof. Roger Kornberg the scientific president of Aposense and SirVir.

Aposense announces that it entered into a license agreement with Processa Pharmaceuticals to license out its anti-cancer pro drug the ATT-11T.   Link to the PR  

SirVir, a subsidiary of Aposense, and the Israeli Institute for Biological Research (IIBR) announce positive results in their pre-clinical collaborative study in the eradication of the Corona virus COVID-19

SirVir, an Aposense subsidiary, announces the accelerated development of a treatment for the COVID-19